Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis

Journal of Cardiovascular Surgery

Volumn 55, Issue 2, 2014, Pages 229-234

  Leopardi, M ^a,b   Houbballah, R ^a   Becquemin, J P ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Angioplasty; Drug eluting stent; Peripheral arterial

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; ALLOY; CARDIOVASCULAR AGENT; NITINOL;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CRITICAL LIMB ISCHEMIA; DOPPLER ECHOGRAPHY; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; FEMALE; FEMOROPOPLITEAL BYPASS; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; NITINOL STENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; RESTENOSIS; STENT THROMBOSIS; SUPERFICIAL FEMORAL ARTERY; VASCULAR PATENCY; DISEASE FREE SURVIVAL; DOPPLER FLOWMETRY; ENDOVASCULAR SURGERY; EQUIPMENT; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTHESIS; RECURRENT DISEASE; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLOYS; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIMB SALVAGE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PROSTHESIS DESIGN; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; VASCULAR PATENCY;

EID: 84900406766     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, BASIL trial participants. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicentre, randomized controlled trial. Lancet 2005;366:1925-34. (Pubitemid 41713982)
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic InterSociety Consensus (TASC). J Vasc Surg 2000;31:S1-S296.
3. Norgren L, Hiatt WR, Dormandy JA. Inter- Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45:S5-S67. (Pubitemid 46151680)
4. Laird JR. Limitadons of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 2006;13:II30:40.
5. Taylor SM, Kalbaugh CA, Healy MG, Cass AL, Gray BH, Langan EM 3rd. Do current outcomes justify more liberal use of revascularization for vasculogenic claudication? A single center experience of 1,000 consecutively treated limbs. J Am Coll Surg 2008;206:1053-62;
6. Ansel G, Lumsden A, Evolving Modalities for Femoropopliteal Interventions J ENDOVASC THER 2009;16:1182-1197.
7. Tosaka A, Soga Y, Iida O. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012;59:16-23.
8. Fajadet J, Morice MC, Bode C, Barragan P, Serruys P, Wijns W. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005;111:1040-4. (Pubitemid 40354523)
9. Gershlick A, Scheerder ID, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel eluting (ELUTES) trial. Circulation 2004;109:487-93. (Pubitemid 38168511)
10. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J Vasc Surg 2007;45:1-67
11. Siracuse JJ, Giles KA, Pomposelli FB, Hamdan AD, Wyers MC, Chaikof EL. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial-femoral artery occlusive disease. J Vasc Surg 2012;55:1001-7.
12. Bosiers M, Peeters P, Tessarek J, Deloose K, Strickler S; Zilver PTX Single-Arm Study Investigators. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg 2013;54:115-22.
13. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, ZilverPTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
14. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, ZilverPTX Investigators. Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. J Am Coll Cardiol 2013;61:2417-27.
15. Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschorner U. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. J Am Coll Cardiol 2013;6:274-81.
16. Al Shammeri O, Bitar F, Ghitelman J, Soukas PA. Viabahn for femoropopliteal in-stent restenosis. Ann Saudi Med 2012;32:572-82.
17. Zeller T, Macharzina R, Tepe G. The potential role of DES in peripheral in-stent restenosis. J Cardiovasc Surg (Torino) 2010;51:561-5.
18. Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol 2012 30;60:1739-42.
19. Fanelli F, Di Primo M, Boatta E, Johnston K, Sapoval M. drug-eluting nitinol stent treatment of the superficial femoral artery and above-the-knee popliteal artery (the Zilver PTX single-arm clinical study): a comparison between diabetic and nondiabetic patients. Cardiovasc Intervent Radiol 2013;36:1232-40.
20. Matas M, Domínguez González JM, Montull E. Antiplatelet therapy in endovascular surgery: the RENDOVASC study. Ann Vasc Surg 2013;27:168-77.
21. Cassar K, Ford I, Greaves M, Bachoo, Brittenden J. Randomized clinical trial of the antiplatelet effects of aspirinclopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg 2005;92:159-65. (Pubitemid 40269328)
22. Wilson AM, Brittenden J, Bachoo P, Ford I, Nixon GF. Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. J Vasc Surg 2009;50:861-9.